Pembrolizumab plus eribulin in hormone-receptor–positive, HER2-negative, locally recurrent or metastatic breast cancer (KELLY): An open-label, multicentre, single-arm, phase Ⅱ trial

José Manuel Pérez-García, Antonio Llombart‐Cussac, María Gión, Giuseppe Curigliano, Elena López-Miranda, José Luis Alonso-Romero, Begoña Bermejo, Lourdes Calvo, Vicente Carañana, Susana de la Cruz Sánchez, Raúl Márquez Vázquez, Aleix Prat, Manuel Ruíz Borrego, Miguel Sampayo-Cordero, Miguel Ángel Seguí, Jesús Soberino, Andrea Malfettone, Peter Schmid, Javier Cortés